Dr. Kerry A. Esquitin, MD

Dr. Esquitin practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Esquitin's NPI, 1861659518, was assigned on May 20, 2008. Dr. Esquitin graduated from Icahn School Of Medicine At Mount Sinai in 2006. Dr. Esquitin's New York license number on file is 249285.

Dr. Esquitin's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Esquitin's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Esquitin is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Esquitin to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Esquitin practices. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Esquitin's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Esquitin is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Esquitin has a license on file in New York.

Dmand AI lists atrial fibrillation and flutter, cerebrovascular disease, chronic hypertension, coronary artery disease, heart blockage, heart failure, heart valve disorders and high cholesterol among the conditions Dr. Esquitin treats.

CMS data shows 530 Medicare services from Dr. Esquitin across 7 procedure codes in 2024, for 282 Medicare patients. Medicare paid $44,265 for them.

CMS counts 282 Medicare patients who saw Dr. Esquitin in 2024. The largest group is 75 to 84, with 118 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.28, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Esquitin's median patient age at 68, with 48% women.

In 2024, Dr. Esquitin wrote 927 Medicare Part D claims for 143 patients. 90% of them were for generic drugs. CMS names the drug for 746 of them, across 18 drugs with 11 or more claims each, at $59,382 in total drug cost. In 2023, CMS named 405 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Esquitin for performance year 2024, reported through an alternative payment model (APM). Dr. Esquitin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Esquitin in 2019. Dr. Esquitin's most frequent co-authors are Isaac George, MD, Rebecca T. Hahn, MD and Martin Bert Leon, MD.

Dmand AI links Dr. Esquitin to 1 clinical trial. Conditions studied include Cardiovascular Diseases.

CMS Open Payments shows 15 general payments to Dr. Esquitin from 11 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Daiichi Sankyo Inc. paid the most, $375.

Dr. Esquitin graduated from Icahn School Of Medicine At Mount Sinai in 2006. Dr. Esquitin is a member of ACC.

Dr. Esquitin is in network with 16 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.